• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nanologica

0.49 SEK

-2.37 %

Less than 1K followers

NICA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.37 %
-32.51 %
+41.14 %
-36.11 %
-29.42 %
-57.59 %
-95.85 %
-96.42 %
-97.25 %

Nanologica is a life science tools company that develops, manufactures and sells advanced input products to pharmaceutical companies. Nanologica's silica-based products are specifically designed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Nanologica operates in a global niche market for drugs for the treatment of diabetes and obesity. Nanologica was founded in 2004 and is headquartered in Södertälje.

Read more
Market cap
162.41M SEK
Turnover
414.16K SEK
Revenue
21.13M
EBIT %
-221.49 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.8
2026

Interim report Q2'26

26.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release01.06.2026, 10.55

NANOLOGICA'S CFO LEAVES THE COMPANY

Nanologica
Press release26.05.2026, 11.45

Redeye: Nanologica (Q1 review): Harvesting season ahead?

Nanologica
Regulatory press release21.05.2026, 15.17

Bulletin from the Annual General Meeting 2026 Nanologica AB (publ)

Nanologica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release20.05.2026, 08.10

Interim Report Q1 2026 Nanologica AB (publ)

Nanologica
Regulatory press release30.04.2026, 10.00

NUMBER OF SHARES AND VOTES IN NANOLOGICA AB (PUBL)

Nanologica
Press release27.04.2026, 09.28

Syntagon AB Recruits Alexandra Pichard Nielsen as Vice President Business Development

Nanologica
Regulatory press release24.04.2026, 08.10

Nanologica AB (publ) Publishes Annual Report for 2025

Nanologica
Regulatory press release23.04.2026, 11.32

Changes in the Management Team of Nanologica AB (publ)

Nanologica
Regulatory press release21.04.2026, 10.17

NOTICE CONVENING THE ANNUAL GENERAL MEETING OF NANOLOGICA AB (PUBL)

Nanologica
Regulatory press release17.04.2026, 07.57

Nanologica AB (publ) Receives Order of appx SEK 2 Million from Customer in India

Nanologica
Regulatory press release31.03.2026, 09.15

NUMBER OF SHARES AND VOTES IN NANOLOGICA AB (PUBL)

Nanologica
Press release29.03.2026, 22.08

EVENT AT NANOLOGICA'S PREMISES – NO DAMAGE TO PERSONNEL OR INSTRUMENTS

Nanologica
Regulatory press release26.03.2026, 20.39

Nanologica Announces Outcome of Rights Issue

Nanologica
Regulatory press release10.03.2026, 09.48

The Nomination Committee Proposes Election of Mark Quick and Erik Haeffler as New Board Members of Nanologica AB (publ)

Nanologica
Regulatory press release10.03.2026, 07.48

Nanologica Announces Outcome of Directed Share Issues

Nanologica
Regulatory press release06.03.2026, 08.28

Nanologica Publishes Information Document Regarding Directed Share Issues and Rights Issue

Nanologica
Regulatory press release04.03.2026, 10.56

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

Nanologica
Regulatory press release26.02.2026, 08.10

Year-End Report 2025 Nanologica AB (publ)

Nanologica
Press release10.02.2026, 09.52

Jeremie Trochu Proposed as New Board Member of Nanologica AB (publ)

Nanologica
Regulatory press release30.01.2026, 08.22

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

Nanologica